摘要
目的探讨肝脏纤维化中天冬氨酸特异性半胱氨酸蛋白酶(Caspase)的表达。方法应用超液化碘油、二氧化硅(SiO_2)晶体及其混合物作用于C57BL/6J小鼠肝右叶3个月后建立局部肝纤维化模型。测量病变组织变性坏死、纤维细胞增生及巨噬细胞和纤维细胞结节的面积大小变化,同时比较病变部位中纤维组织Caspase-3表达的阳性率。结果三组小鼠变性坏死面积不同,其中混合液组局部变性坏死面积最大(P<0.01);混和液组与碘油组比较变性坏死面积差异无统计学意义(P>0.05),碘油组与混和液组均引起肝纤维组织增生,而混和液组致肝纤维化较碘油组更明显(P<0.01),混和液组中出现巨噬细胞和纤维细胞性结节,个别结节有玻璃样变。免疫组织化学显示,对照组门汇管区与SiO_2组纤维化病灶内纤维细胞Caspase-3表达的阳性率分别为(20.0±5.7)%和(35.0±11.2)%(P<0.01)。结论SiO_2与超液化碘油的联合应用可以选择性地引起肝组织纤维化,其机制可能与Caspase-3的表达作用有关。
Objective To explore the expression of Caspase-3 in selective hepatic fibrosis. Methods The models of regional hepatic fibrosis were established with the application of ultra-liquefied lipiodol, SiO2 crystal and their mixture on right hepatic lobes of mice (C57BL/6J) for 3 months. The changes of degeneration and necrosis ,fibrocytie proliferation and maerocytie and fibrocytie nodules in pathological tissues were measured, and the positive rate of Caspase-3 expression in fibrotie tissues was compared as well. Results There were differences in areas of degeneration and necroses among the 3 groups,in which the largest area of degenerative necrosis was found in the mixture group ( P 〈 0.01 ) ; No significant difference was found between mixture and lipiodol groups ( P 〉 0.05 ). Both the lipiodol and the mixture groups had fibrotie tissue proliferation of liver, and in mixture group hepatic fibrosis was more obvious than in lipiodol group (P 〈 0.01 ). Maerocytie and fibrocytie nodules appeared in mixture group, and some nodules showed hyaline degeneration. Immunocbemistry revealed the positive expression rate of Caspase-3 in fibrotie cells in hepatic portal tubular area of control group and that in fibrosed nidus of SiO2 group was (20.0±5.7)% and (35.0±11.2)% respectively (P〈0.01). Conclusion Combined used of SiO2 and ultra-liquefied lipiodol may selectively result in hepatic tissue fibrosis possibly by inducing the Caspase-3 expression.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2007年第5期546-547,共2页
Chinese Journal of Experimental Surgery
基金
广东省科技计划资助项目(2005B30301016)
关键词
二氧化硅
肝纤维化
碘油
Silicon dioxide
Hepatic fibrosis
Lipiodol